Eli Lilly’s dominant incretin franchise, expanding obesity TAM, and retatrutide pipeline support a premium-priced secular compounder despite regulatory and concentration risks.
Overview
Eli Lilly is a global biopharmaceutical company whose high-margin portfolio spans cardiometabolic health, oncology, immunology, and neuroscience. Its financial trajectory is now dominated by Mounjaro and Zepbound, while Foundayo and retatrutide extend the oral and next-generation obesity opportunity. Lilly holds 60.9% of the U.S. incretin market and 54.9% internationally, ahead of Novo Nordisk. **Q2 2026 revenue rose 48% to $22.974 billion**, beating consensus by $2.41 billion, while 60% volume growth more than offset a 13% decline in realized global pricing. Non-GAAP operating margin expanded to 54.8%, and full-year 2026 revenue guidance increased to $85.0-$87.0 billion. The normalized TTM P/E of approximately 39.7x and Price/Sales of 13.9x reflect a substantial premium, but the valuation is supported by 23.17% FY2021-FY2025 revenue CAGR, 46.6% 2025 ROCE, and expected FCF of $17 billion in 2026 and over $27 billion in 2027. Near-term catalysts include continued tirzepatide volume growth, Foundayo adoption, international expansion, and retatrutide regulatory progress. The principal counterweights are IRA pricing pressure, concentration in tirzepatide, manufacturing execution, and premium-multiple compression.